- +918296714532
- allthatscancer@gmail.com
-
Bengaluru
Benign breast disease is a key indicator of a higher risk of breast cancerBenign breast disease is a key indicator of a higher risk of breast cancer
According to research presented at the 13th European Breast cancer Conference on 17th Nov’22, women diagnosed with benign breast diseases such as fibroadenomas and cysts are at a higher risk of breast cancer.
Breast cancer spread uncovered by new molecular microscopyBreast cancer spread uncovered by new molecular microscopy
A new tool can map the breast can cell responsible for the spread of the disease along with its location.
Popular ‘anti-aging’ supplement may lead to brain cancerPopular ‘anti-aging’ supplement may lead to brain cancer
According to a study at University of Missouri, taking an anti-aging vitamin supplement called nicotinamide riboside, a variant of B3, may increase the risk of brain cancer.
Early treatment of COVID-19 crucial for patients with cancerEarly treatment of COVID-19 crucial for patients with cancer
According to the latest news, early treatment of COVID-19 crucial for cancer patients. The treatment, vaccines and preventive measures for COVID-19 have improved safety and outcomes for cancer patients significantly.
CAR-T destined for earlier lines of therapy in blood cancers, experts sayCAR-T destined for earlier lines of therapy in blood cancers, experts say
According to researchers at Chemotherapy Foundation Symposium the chimeric antigen receptor T cells have the possibility to become front-line therapy for multiple hematologic malignancies.
Opdivo Approved in Head and Neck Cancer SubsetOpdivo Approved in Head and Neck Cancer Subset
Use of FDA (Food and Drug Administration) approved Opdivo (nivolumab) has shown tremendous improvement in the survival rate of head & neck cancer patients and it also has fewer side effects when compared to standard chemo.
Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
According to a new research biomarkers are used to predict the benefits of immunotherapy in head & neck cancer patients. However, the commercial use of these biomarkers is yet not approved.
FDA approves Adcetris with chemotherapy for children with high-risk Hodgkin lymphomaFDA approves Adcetris with chemotherapy for children with high-risk Hodgkin lymphoma
FDA has approved use of brentuximab vedotin (Adcetris, Seagen), an antibody-drug conjugate in combination with chemotherapy for treatment of Hodgkin lymphoma in children.
CAR-T effective for younger patients with leukemia, regardless of socioeconomic statusCAR-T effective for younger patients with leukemia, regardless of socioeconomic status
According to a latest study, socio-economic status has no effect on the full remission rate of children with B-cell acute lymphoblastic leukemia receiving chimeric antigen receptor T-cell therapy.
European Commission Approves Cemiplimab for Recurrent or Metastatic Cervical CancerEuropean Commission Approves Cemiplimab for Recurrent or Metastatic Cervical Cancer
“The European Commission has approved cemiplimab-rwlc (Libtayo) monotherapy for the treatment of recurrent or metastatic cervical cancer in adult patients who have progressed on or after platinum-based chemotherapy.”
FDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian CancerFDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian Cancer
“The FDA has approved the VENTANA FOLR1 (FOLR1-2.1) RxDx assay, the first immunohistochemistry (IHC) companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx (Elahere).”
USFDA declines to approve Spectrum Pharmaceuticals’ lung cancer drugUSFDA declines to approve Spectrum Pharmaceuticals’ lung cancer drug
Due to the need for additional study, the FDA has declined approval of an experimental lung cancer drug by Spectrum Pharmaceuticals Inc.
Multidisciplinary Approach Leads to Higher Rate of Neoadjuvant Treatment Completion in Pancreatic CancerMultidisciplinary Approach Leads to Higher Rate of Neoadjuvant Treatment Completion in Pancreatic Cancer
According to the findings of a study presented at the American Society of Clinical Oncology’s Quality Care Symposium 2022, “patients with localized pancreatic adenocarcinoma receiving care at multidisciplinary clinic had significantly higher neoadjuvant therapy completion rates than those treated at a specialty-specific clinic.
Bemarituzumab Improves OS, Not PFS, in Gastric and GEJ CancerBemarituzumab Improves OS, Not PFS, in Gastric and GEJ Cancer
According to a study published in The Lancet Oncology, “adding bemarituzumab to standard chemotherapy improves overall survival (OS) in patients with FGFR2b-expressing advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.”
Researchers discover a molecule that promotes tumor cell survival in retinoblastomaResearchers discover a molecule that promotes tumor cell survival in retinoblastoma
According to the latest research report at UT Southwestern and the University of Miami, it has been discovered that a molecule named estrogen-related receptor gamma, or ESRRG is responsible for the growth and survival of retinoblastoma. According to the report, blocking ESRRG destroys retinoblastoma cells.
New Hope Against a Rare but Incurable Eye CancerNew Hope Against a Rare but Incurable Eye Cancer
According to the latest news report by American Association of Cancer Research (AACR), “Tebentafusp has now become the first drug shown to improve overall survival in patients with uveal melanoma.”
Mouth cancer rates hit record highMouth cancer rates hit record high
New cases of mouth cancer are on rise in the UK, says the new finding in State of Mouth Cancer UK Report 2022.
Oral cancer on the rise among youngOral cancer on the rise among young
Cases of oral cancer are on rise among youths, says the latest news report.
Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapyAdvanced melanoma survival improves significantly when immunotherapy is given before targeted therapy
As per the latest findings at a clinical trial at Georgetown Lombardi Comprehensive Cancer Center, it has been found that “advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy.”
Artificial intelligence-based method may help predict early-stage melanoma recurrenceArtificial intelligence-based method may help predict early-stage melanoma recurrence
Massachusetts General Hospital (MGH) researchers have developed an AI (artificial intelligence) based method to predict early-stage melanoma recurrence
Patients With Axial Osteosarcoma May Have Higher Risk for Local RecurrencePatients With Axial Osteosarcoma May Have Higher Risk for Local Recurrence
As per a new analysis of the EURAMOS-1 study published in BMJ Open, “Patients with osteosarcoma at axial sites have an increased risk for local recurrence after surgery.”
Osteosarcoma Incidence Highest in Black PatientsOsteosarcoma Incidence Highest in Black Patients
According to a report published in Cancer, “osteosarcoma incidence highest in black patients.”
Preoperative Fibrinogen-to-Albumin Ratio as Potential Predictor of Bladder Cancer: A Monocentric Retrospective StudyPreoperative Fibrinogen-to-Albumin Ratio as Potential Predictor of Bladder Cancer: A Monocentric Retrospective Study
A Monocentric Retrospective Study explores the preoperative Fibrinogen-to-Albumin ratio as potential predictor of bladder cancer
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022)Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2022)
“The American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO), released the 2022 clinical practice guideline for the management of clinically localized prostate cancer.”